MedTrace Logo

Characterization of Natural IL-6 Inhibition in Healthy Individuals

NCT05867524 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-05-22

No results posted yet for this study

Summary

The aim of the project is to investigate whether or not there are any difference in cardiometabolic outcomes in individuals with high or low levels of c-aAb against interleukin-6 (IL-6).

The study is the first to investigate individuals with extreme amounts of c-aAb levels against IL-6 and to contribute with knowledge on a possible new phenotype.

Conditions

  • Autoantibodies
  • Interleukin-6

Interventions

OTHER

Oral Glucose Tolerance Test

75g oral glucose tolerance test, sampled over three hours

OTHER

Cycling test

2 hours of moderate activity level cycling

Sponsors & Collaborators

  • Clinical Immunological Department, Rigshospitalet

    collaborator UNKNOWN

  • The Danish Blood Donor Study

    collaborator UNKNOWN

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Torben Hansen, PhD · University of Copenhagen

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2024-02-01
Completion
2024-02-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05867524 on ClinicalTrials.gov